Sugi Predict

Sugi Predict / Compounds / Geiparvarin

Geiparvarin

Geiparvarin

SCHEMBL2532495

CC(=CCOc1ccc2ccc(=O)oc2c1)C1=CC(=O)C(C)(C)O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 5/20 1.00
▸ CA12 O43570 4/20 1.00
▸ CA1 P00915 4/20 1.00
▸ CA9 Q16790 4/20 1.00
▸ CA7 P43166 3/20 1.00
▸ CA13 Q8N1Q1 3/20 1.00
▸ MAOA P21397 2/20 1.00
▸ PAX8 Q06710 1/20 1.00
▸ KDM4E B2RXH2 4/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ MTNR1A P48039 2/20 0.64
▸ CA2 P00918 1/20 0.59
▸ NDUFS8 O00217 3/20 0.56
▸ COXFA4 O00483 3/20 0.56
▸ NDUFAB1 O14561 3/20 0.56
▸ NDUFA1 O15239 3/20 0.56
▸ NDUFS4 O43181 3/20 0.56
▸ NDUFB5 O43674 3/20 0.56
▸ NDUFB3 O43676 3/20 0.56
▸ NDUFC1 O43677 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Geiparvarin SCHEMBL12247773 1.00 MAOB (1.00) MAOBCA12CA1CA9CA7
Geiparvarin SCHEMBL31130089 1.00 MAOB (1.00) MAOBCA12CA1CA9CA7
7-Prenyloxycoumarin SCHEMBL4898255 0.79 KDM4E (1.00) MAOBCA12CA1CA9CA7
SCHEMBL18265492 0.76 KDM4E (0.78) MAOBCA12CA1CA9CA7
SCHEMBL29835955 0.73 KDM4E (0.69) CA12CA1CA9CA7CA13
Auraptene SCHEMBL2535034 0.72 ALOX15 (1.00) MAOBCA12CA1CA9CA7
SCHEMBL29999425 0.72 NDUFS8 (0.83) CA12CA1CA9CA7CA13
Auraptene SCHEMBL2535029 0.72 ALOX15 (1.00) MAOBCA12CA1CA9CA7
SCHEMBL24700226 0.71 NDUFS8 (0.81) CA12CA1CA9CA7CA13
Umbelliprenin SCHEMBL18265478 0.71 ALOX15 (1.00) MAOBCA12CA1CA9CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110787160-A Application of Geiparvarin in preparation of anti-osteosarcoma product 中国人民解放军陆军特色医学中心 2020-02-14 — — CN claimed
US-20070293563-A1 Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission DSM IP ASSETS B.V. (NL) 2007-12-20 — — US claimed
CN-101043886-A Novel agents for the prevention and treatment of disorders associated with impaired neurotransmission DSM IP ASSETS BV (NL) 2007-09-26 — — CN claimed
EP-1802298-A2 NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION DSMIP Assets B.V. (NL) 2007-07-04 — — EP claimed
WO-2006042441-A2 NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION DSM IP ASSETS B.V. (NL) 2006-04-27 — — WO claimed
JP-58013571-A — — None — — JP disclosed
CN-116444532-A Porphyrin warfarin derivative and preparation method and application thereof 南华大学 2023-07-18 — — CN disclosed
CN-110787160-A Application of Geiparvarin in preparation of anti-osteosarcoma product 中国人民解放军陆军特色医学中心 2020-02-14 — — CN disclosed
CN-110787160-A Application of Geiparvarin in preparation of anti-osteosarcoma product 中国人民解放军陆军特色医学中心 2020-02-14 — — CN disclosed
CN-110787160-A Application of Geiparvarin in preparation of anti-osteosarcoma product 中国人民解放军陆军特色医学中心 2020-02-14 — — CN disclosed
CN-106008476-B 3- (2-aryl-1H-indole-3-yl) -4-hydroxycoumarin derivative and synthetic method thereof 苏州大学 2019-02-26 — — CN disclosed
CN-106008476-A 3- (2-aryl-1H-indole-3-yl) -4-hydroxycoumarin derivative and synthetic method thereof 苏州大学 2016-10-12 — — CN disclosed
US-20050148665-A1 Reagents and method for spatio-temporal control of gene expression by illumination NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2005-07-07 — — US disclosed
WO-2004098651-A2 BONE LOCALISING RADIOPHARMACEUTICAL AND TUBULIN-INTERACTING COMPOUND COMBINATORIAL RADIOTHERAPY SCHERING AG (DE) 2004-11-18 — — WO disclosed
EP-1475105-A1 Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy Schering AG (DE) 2004-11-10 — — EP disclosed
US-6803479-B2 PHOTOCHEMISTRY RELEASING UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE 2004-10-12 — — US disclosed
US-20040180393-A1 Chromogenic substrates of sialidase of bacterial, viral, protozoa and vertebrate origin and methods of making and using the same IBBEX, INC. 2004-09-16 — — US disclosed
US-6667161-B1 Measuring sialidase activity IBBEX, INC. 2003-12-23 — — US disclosed
US-20030018073-A1 Reagents and method for spatio-temporal control of gene expression by illumination MARYLAND BIOTECHNOLOGY INSTITUTE, UNIVERSITY OF 2003-01-23 — — US disclosed
JP-S5813571-A DIHYDROFURAN DERIVATIVE AND ITS PREPARATION SAGAMI CHEM RES CENTER 1983-01-26 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148665-A1 Reagents and method for spatio-temporal control of gene expression by illumination ERG, NR2E3, PSMD2 MAOB 3122/4885CA12 1067/4885CA1 290/4885
US-20070293563-A1 Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission CHRNA2, CHRM1, CHRM5 MAOB 187/4885CA12 3935/4885CA1 3080/4885
US-20030018073-A1 Reagents and method for spatio-temporal control of gene expression by illumination ERG, NR2E3, NEFM MAOB 1963/4885CA12 398/4885CA1 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.